

## AMENDMENTS

### In the Claims:

Please amend paragraph [0007] as indicated below. The paragraph is marked with a ~~strike through~~ to designate deletions and underlining to designate additions.

[0007] Several commercial forms of Factor VIII concentrates are available to provide replacement therapy for patients suffering from hemophilia A. For example, blood-derived Factor VIII concentrate products sold under the ~~Hemofil<sup>®</sup>-M~~ HEMOFIL<sup>®</sup> M (Baxter, Deerfield, IL), ~~Koate<sup>®</sup>-DVI~~ KOATE<sup>®</sup>-DVI (Bayer, Research Triangle Park, NC), ~~Monarc-M<sup>TM</sup>~~ MONARC-M<sup>TM</sup> (American Red Cross, Washington, D.C.), and ~~Monoclade-P<sup>®</sup>~~ MONOCLATE-P<sup>®</sup> (Aventis, Bridgewater, NJ) brands. With respect to recombinantly prepared Factor VIII concentrates, commercial products are provided under the ~~Helixate<sup>®</sup>-FS~~ HELIXATE<sup>®</sup> FS (Aventis, Bridgewater, NJ), ~~Kogenate-FS<sup>®</sup>~~ KOGENATE FS<sup>®</sup> (Bayer, Research Triangle Park, NC), ~~Recombinate<sup>®</sup>~~ RECOMBINATE<sup>®</sup> (Baxter, Deerfield, IL), ~~Advate<sup>®</sup>~~ ADVATE<sup>®</sup> (Baxter, Deerfield, IL), and ~~ReFacto<sup>®</sup>~~ REFACTO<sup>®</sup> (Wyeth/Genetics Institute, Cambridge, MA) brands.